Molly Olm-Shipman on Preserving Autonomy in Patients with Breast Cancer

Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

Telephone and Web-Based Program Elicits Clinically Meaningful Results in Breast Cancer Survivors

A Look Back at 2022 FDA Approvals in Oncology

Capivasertib Demonstrates Potential PFS Advantage in HR+ Advanced Breast Cancer

Preoperative Treatment with Atezolizumab/Epirubicin Plus Trastuzumab/Pertuzumab Elicits High pCR Rate in Patients With Early HER2+ Positive Breast Cancer

Ribociclib Plus Fulvestrant Leads to Longer PFS in Metastatic Breast Cancer

Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

Telephone and Web-Based Program Elicits Clinically Meaningful Results in Breast Cancer Survivors

A Look Back at 2022 FDA Approvals in Oncology

Capivasertib Demonstrates Potential PFS Advantage in HR+ Advanced Breast Cancer

Preoperative Treatment with Atezolizumab/Epirubicin Plus Trastuzumab/Pertuzumab Elicits High pCR Rate in Patients With Early HER2+ Positive Breast Cancer

Ribociclib Plus Fulvestrant Leads to Longer PFS in Metastatic Breast Cancer

Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

Telephone and Web-Based Program Elicits Clinically Meaningful Results in Breast Cancer Survivors

A Look Back at 2022 FDA Approvals in Oncology

Capivasertib Demonstrates Potential PFS Advantage in HR+ Advanced Breast Cancer

Preoperative Treatment with Atezolizumab/Epirubicin Plus Trastuzumab/Pertuzumab Elicits High pCR Rate in Patients With Early HER2+ Positive Breast Cancer

Ribociclib Plus Fulvestrant Leads to Longer PFS in Metastatic Breast Cancer

Related Content

Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

Patients with metastatic breast cancer who received ribociclib plus fulvestrant achieved a median progression-free survival of 18.1 months vs 5.29 months with placebo/fulvestrant.

Telephone and Web-Based Program Elicits Clinically Meaningful Results in Breast Cancer Survivors

Podcast

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.

A Look Back at 2022 FDA Approvals in Oncology

A telephone-based weight loss program proved to be efficacious in overweight or obese women with breast cancer and may lead to improved disease outcomes in the long run.

Capivasertib Demonstrates Potential PFS Advantage in HR+ Advanced Breast Cancer

Podcast

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Preoperative Treatment with Atezolizumab/Epirubicin Plus Trastuzumab/Pertuzumab Elicits High pCR Rate in Patients With Early HER2+ Positive Breast Cancer

Combined treatment with capivasertib plus fulvestrant yielded a 5.5-month median progression-free survival for patients with HR+ advanced breast cancer.